World Cancer Day in Kenya: A Commemoration of Hope

Cancer continues to pose a major global public health challenge. Multiple factors including ageing populations due to improved life expectancy, unhealthy behaviors such as tobacco and alcohol use, infections like HPV and environmental exposures are contributing to the growing cancer burden worldwide. Many people ask what they can do to prevent cancer, yet some cancers arise from inherited or sporadic genetic mutations beyond individual control. In such cases, early diagnosis remains the most powerful tool for improving outcomes.

In Kenya, cancer is now among the leading causes of morbidity and mortality, generally ranked as the third leading cause of death after cardiovascular and renal disease. An estimated 50,000 new cancer cases are diagnosed each year, a figure that likely underestimates the true burden, as some patients die before histological confirmation can be obtained. Alarmingly, nearly half of those diagnosed will succumb to the disease.

The apparent rise in cancer cases over the past decade is partly attributable to improved diagnostic capacity. The Managed Equipment Service (MES), launched in 2015, enabled the installation of diagnostic equipment in many public hospitals across the country, allowing cancers that previously went undetected or were misclassified to be correctly diagnosed.

Cancer has touched nearly every Kenyan household. Over two-thirds of patients present with advanced disease, when cure is unlikely and long-term treatment or palliation becomes necessary. Early-stage cancer, by contrast, is often curable, easier to manage and significantly less costly.

Beyond the clinical burden, cancer places immense emotional, psychosocial and financial strain on individuals, families and the health system. Access to prevention, diagnosis, treatment and supportive care remains uneven, disproportionately affecting poorer populations. Notably, even among the approximately 20% of Kenyans with private health insurance, uptake of preventive and screening services remains low and many still present with advanced disease. Once diagnosed, patients are often categorized as having “chronic” illness, with limited financial cover that is rapidly exhausted.

Cancer is more likely to respond to treatment when detected early. Expanding screening, strengthening early diagnosis and ensuring prompt initiation of care would markedly improve survival. Equally essential are psychosocial support and palliative care services, which preserve dignity and quality of life for patients and their families.

World Cancer Day, commemorated annually on 4 February, serves as a global platform to raise awareness on prevention, early detection and equitable access to care. Open conversations about cancer help reduce stigma and encourage policymakers to invest in cancer services both materially and through workforce development.

The 2025–2027 World Cancer Day theme, “United by Unique,” underscores the importance of people-centered cancer care. While every cancer journey is individual, progress depends on collective commitment to compassion, equity and system-wide solutions.

Despite expanded access to diagnosis and treatment through the former National Health Insurance Fund (NHIF) and the current Social Health Authority (SHA), cancer care in Kenya remains fragmented. The human cost of this fragmentation is evident in the experiences of patients like Sabina and Rose.

Sabina was diagnosed in 2024 with malignant melanoma of the genital region a rare and aggressive cancer. The standard of care involves immunotherapy, with a palliative dose costing approximately KES 800,000 every three weeks for up to a year to control symptoms and preserve quality of life.

Rose, a 42-year-old mother of three who earns a living washing clothes in Nairobi’s Buruburu area, was diagnosed with stage IV HER2-positive breast cancer in 2024. Her treatment costs range between KES 200,000 and 300,000 per dose every three weeks, often required for months or years.

In contrast, patients with hormone-sensitive prostate or breast cancer can achieve excellent outcomes with androgen deprivation or hormonal therapy costing between KES 3,000 and 11,000 per month.

These stark disparities not only in drug costs but also in diagnostics pose difficult questions for our health financing systems.

• Who should be prioritized for support? Patients with early-stage, potentially curable disease?
• Those with metastatic disease requiring lower-cost palliation?
• Or patients whose treatments are highly effective but financially prohibitive?

Families are often forced to choose between financing treatment and meeting basic needs. Yet with access to appropriate therapy, even patients with advanced disease can live for years with good quality of life. Fair and sustainable allocation of limited resources requires evidence-based protocols that maximize survival while upholding dignity.

Kenya can alter its cancer trajectory through HPV vaccination, highly sensitive and cost-effective screening and decentralized treatment of precancerous lesions to prevent progression to malignancy.

United by Unique. Every story counts. Every patient matters.